Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/infdis/jiaa152 http://scihub22266oqcxt.onion/10.1093/infdis/jiaa152 32232474!7184325!32232474     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Infect+Dis 2020 ; 221 (11): 1752-1756 Nephropedia Template TP {{tp|p=32232474|t=2020. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure |pdf=|usr=}}{{32232474}} gab.com Text Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure JO: J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32232474 #FOAvip Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care. Twit Text FOAVip Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure ????J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32232474 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32232474 #FOAvip English Wikipedia <ref>{{Cite pmid|32232474}}</ref> Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure #MMPMID32232474 Eyal N; Lipsitch M; Smith PG J Infect Dis 2020[May]; 221 (11): 1752-1756 PMID32232474show ga Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care. |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Clinical Trials as Topic/*standards[MESH] |Coronavirus Infections/*prevention & control[MESH] |Drug Development/*trends[MESH] |Humans[MESH] |Licensure[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*prevention & control[MESH] |SARS-CoV-2[MESH]Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure (epmc).pdf DeepDyve Pubget Overpricing